Altimmune (ALT) Operating Expenses (2010 - 2026)

Altimmune (ALT) has reported Operating Expenses for 17 consecutive years, with $24.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 11.11% year-over-year to $24.2 million; the TTM figure through Mar 2026 stood at $97.0 million (down 1.28% YoY), while the FY2025 annual figure was $94.5 million, down 8.39% from the prior year.
• Operating Expenses fell to $24.2 million in Q1 2026 per ALT's latest filing, from $28.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $33.7 million in Q4 2023 and bottomed at $18.0 million in Q2 2023.
• Historically, Operating Expenses has averaged $23.9 million across 5 years, with a median of $23.0 million in 2022.
• On a YoY basis, Operating Expenses climbed as much as 48.5% in 2024 and fell as far as 26.11% in 2024.
• Altimmune's Operating Expenses stood at $23.0 million in 2022, then jumped by 46.45% to $33.7 million in 2023, then decreased by 26.11% to $24.9 million in 2024, then advanced by 16.28% to $28.9 million in 2025, then retreated by 16.17% to $24.2 million in 2026.
• Business Quant data shows ALT's Operating Expenses at $24.2 million in Q1 2026, $28.9 million in Q4 2025, and $20.9 million in Q3 2025.